Roche’s chronic cough program has sputtered to a halt. The drugmaker, which axed the program after the drug candidate ...

Roche will use Dyno’s technology, through which Dyno applies AI and high-throughput in vivo data collection to engineering ...

With an upfront payment of $50 million from Roche, the partnership will leverage Dyno Therapeutics’ in vivo gene therapy ...

Prasinezumab是一种人源化单克隆抗体，是首个被设计用来靶向α-突触核蛋白（α-Syn）从而促进其降解的实验性单克隆抗体，有望通过抑制致病性的α-突触核蛋白在细胞间的扩散来保护神经元、减缓帕金森病进展。

Jefferies analyst Peter Welford noted that Roche’s pharma group came just slightly ahead of consensus expectations, driven by ...

About 500 children worldwide have received the gene therapy, including some families traveling abroad to gain access to it.

Roche Holding AG said its third-quarter sales rose thanks to eye drug Vabysmo as well as medicines for cancer, hemophilia and ...

Swiss pharma giant Roche is refocusing its R&D investment on diseases like obesity that weigh heavily on healthcare budgets.

Over the last couple of years, one of the biggest stories in the stock market has been around pharmaceutical companies that ...

And while we often feel the dryness on our face first, our hands and legs experience it, too, shares Dr. Azadeh Shirazi, ...

Vyloy is the first CLDN18.2-targeted treatment to reach the US market alongside Roche's Ventana CLDN18 RxDx Assay for identifying eligible patients.

周四，H.C. Wainwright重申了对Poseida Therapeutics, Inc (NASDAQ:PSTX)的买入评级，目标股价为$20.00。这一确认是在该公司于2024年9月27日在国际骨髓瘤协会年会上发布了一项正在进行的研究的积极数据之后做出的。这项与Roche合作进行的研究正在评估P-BCMA-ALLO1用于治疗复发和难治性多发性骨髓瘤(r/r MM)。 研究中重点关注的数据 ...